Fezolinetant in Focus: Key Findings From the SKYLIGHT Trials

Key Takeaways

• Fezolinetant's approval was based on SKYLIGHT 1, 2, and 4 trials, which were randomized, double-blind, and placebo-controlled.
• The trials focused on women with moderate to severe vasomotor symptoms, evaluating fezolinetant's safety and efficacy.
• Significant reductions in VMS frequency and severity were observed with fezolinetant compared to placebo.
• Safety profiles were favorable, with adverse events similar to placebo, highlighting fezolinetant's potential as a non-hormonal treatment option.